Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2023 Third Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that thereare no false representations, misleading statements or material omissions contained inthis announcement and accept legal responsibility for the truthfulness, accuracy andcompleteness of the contents hereof.
IMPORTANT NOTICE:
? The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior managementof the Company hereby warrant the truthfulness, accuracy and completeness of the contents of thisquarterly report, and that there are no false representations, misleading statements or materialomissions contained herein, and severally and jointly accept legal responsibility.
? The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-
charge of the accounting department (the head of the accounting department) hereby warrant thetruthfulness, accuracy and completeness of the financial information contained in this quarterly report.
? Whether the third quarterly financial statements have been audited.
□Yes √No
I. MAJOR FINANCIAL DATA(I) Major Accounting Data and Financial Indicators
Unit: Yuan Currency: RMB
| Item | For the Reporting Period (From July to September) | YoY change (%) | From the beginning of the year to the end of the Reporting Period | YoY change (%) |
| Revenues | 3,931,515,787.21 | -11.59 | 12,651,257,386.44 | -2.77 |
| Net profit attributable to Shareholders of the listed company | 268,214,419.85 | -17.55 | 1,083,649,154.75 | -3.81 |
| Net profit attributable to Shareholders of the listed company after deduction of extraordinary gains and losses | 267,477,595.49 | -14.37 | 1,049,221,737.67 | -6.01 |
| Net cash flow from operating activities | N/A | N/A | 2,459,851,744.70 | -5.72 |
| Basic earnings per share (RMB/share) | 0.1418 | -18.87 | 0.5682 | -5.03 |
| Diluted earnings per share (RMB/share) | 0.1412 | -18.83 | 0.5663 | -5.17 |
| Weighted average return on net assets (%) | 1.93 | Decreased by 0.80 percentage points | 8.22 | Decreased by1.16 percentage points |
| As at the end of the Reporting Period | As at the end of the previous year | Change in the ending amount of the Reporting Period to that of the previous (%) | ||
| Total assets | 35,769,669,256.09 | 35,729,253,651.41 | 0.11 | |
| Net assets attributable to Shareholders of the listed company | 13,337,938,211.52 | 13,121,820,410.55 | 1.65 | |
Notes: 1. The “Reporting Period” refers to the three-month period from the beginning to the end of this quarter,the same below.
2. From January to September 2023, the Company Chemical pharmaceuticals realized revenues ofRMB6,572 million, representing a YoY decrease of 9.20%, among which, RMB1,112 million were fromrespiratory formulation products, representing a YoY increase of 28.98%; RMB400 million were from anti-infection products, representing a YoY decrease of 65.23%; RMB2,279 million were from gastroenterologyproducts, representing a YoY decrease of 12.93%; RMB2,188 million were from gonadotropic hormones,representing a YoY increase of 4.94%; and RMB430 million were from psychiatry products, representing aYoY increase of 7.60%. APIs and intermediates products realized revenues of RMB3,970 million, representinga YoY decrease of 2.07%. Traditional Chinese Medicine products realized revenues of RMB1,291 million,representing a YoY increase of 49.48%. Diagnostic reagents and equipment products realized revenues ofRMB468 million, representing a YoY decrease of 6.88%. Health care products realized revenues of RMB132million, representing a YoY increase of 60.12%. Biological products realized revenues of RMB113 million,representing a YoY decrease of 31.09%.
3. From January to September 2023, the Company realized net profit attributable to shareholders of theparent of RMB1,084 million, of which Joincare (excluding Livzon Group and Livzon MAB) realized net profitattributable to shareholders of the parent of approximately RMB612 million, representing a YoY decrease ofapproximately 4.17%, and the impact of Livzon MAB on the net profit attributable to shareholders of the parentwas approximately negative RMB412 million.
(II) Items and Amounts of Extraordinary Gains and Losses
Unit: Yuan Currency: RMB
| Item | For the Reporting Period | From the beginning of the year to the end of the Reporting Period |
| Gains and losses on disposal of non-current assets | 141,880.83 | -200,478.63 |
| Government grants as included in the profit or loss for the Period, however, except for those which are closely related to the normal business of an enterprise, comply with thepolicies of the State and are continuously entitled with specific amount or quantity according to certain standards | 25,392,502.84 | 148,737,247.12 |
| Gains and losses on fair value changes incurred from financial assets held for trading, derivative financial assets, financial liabilities held for trading and derivative financial liabilities, and investment income on disposal of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and other debt investments, except for effective hedging activities related to the ordinary operating business of the Company | -21,111,799.30 | -66,463,191.33 |
| Other non-operating income and expenses excluding the above items | -11,850,546.09 | -17,463,124.32 |
| Less: Effect of income tax | 1,076,795.55 | 13,107,981.50 |
| Effect of minority equity (after tax) | -9,241,581.63 | 17,075,054.26 |
| Total | 736,824.36 | 34,427,417.08 |
Explanations for classifying items of extraordinary gains and losses defined in the ExplanatoryAnnouncement No. 1 for Public Company Information Disclosures –Extraordinary Gains or Losses asitems of recurring gains or losses.
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Thereof
□Applicable √N/A
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and ReasonsThereof
Unit: Yuan Currency: RMB
| Balance Sheet | 30 September 2023 | 31 December 2022 | Change in proportion （%） | Main Reason |
| Financial assets held for trading | 73,193,659.40 | 109,015,664.98 | -32.86 | Mainly due to fluctuations in market value of the securities investment held. |
| Non-current assets due within one year | 362,830,383.78 | 54,048,611.11 | 571.30 | Mainly due to an increase in large-denomination of deposit maturing within one year. |
| Construction in progress | 562,135,145.68 | 811,300,068.96 | -30.71 | Mainly due to the production lines of new factories and workshops of the subsidiaries transferred to fixed assets. |
| Financial liabilities held for trading | 10,966,528.06 | 755,634.43 | 1,351.30 | Mainly due to the changes in fair value of foreign currency forward contracts. |
| Contract liabilities | 75,564,862.24 | 292,977,730.74 | -74.21 | Mainly due to some contract performance obligations during the current period, which satisfies the conditions for revenues |
| recognition and results in the carrying forward of revenue. | ||||
| Other current liabilities | 45,432,846.70 | 101,276,714.35 | -55.14 | Mainly due to the decrease in estimated refund payable. |
| Lease liabilities | 14,438,999.56 | 23,482,486.07 | -38.51 | Mainly due to the decrease in lease contracts signed during the period, leading to a decrease in lease payables. |
| Treasury shares | 564,252,205.84 | 347,176,561.29 | 62.53 | Mainly due to the repurchase of A shares of the Company during the Period. |
| Statement of Income | January to September 2023 | January to September 2022 | Change in proportion （%） | Main Reason |
| Gains from changes in fair values | -46,003,628.22 | -86,989,533.83 | N/A | Mainly due to fluctuations in market value of the securities investment held. |
| Credit impairment loss | -17,737,505.85 | -9,508,656.53 | N/A | Mainly due to changes in the aging of accounts receivables, leading to the corresponding increase in expected credit loss during the Period. |
| Gains from disposal of assets | -200,478.63 | 1,121,679.66 | -117.87 | Mainly due to gains incurred from disposal of fixed assets during the previous period. |
| Non-operating expenses | 23,765,998.31 | 13,738,456.89 | 72.99 | Mainly due to the increase in expenditure of charitable donation for the period as compared with the previous period. |
| Other comprehensive income –net of tax | -22,658,520.87 | 80,412,282.94 | -128.18 | Mainly due to changes in the fair value of other equity instrument investments and exchange rate fluctuations resulting in changes in translation differences of foreign currency financial statements. |
| Cash Flow Statement | January to September 2023 | January to September 2022 | Change in proportion （%） | Main Reason |
| Net cash flows from financing activities | -1,987,651,014.91 | 873,841,344.96 | -327.46 | Mainly due to the issuance of GDRs (Global Depository Receipts) and the increase in loans in the same period of the previous year. |
II. SHAREHOLDERS(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with RestoredVoting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
| Total number of holders of ordinary shares as of the end of the Reporting Period | 79,393 | Total number of holders of preferred shares with restored voting rights as of the end of the Reporting Period (if any) | 0 |
| Shareholdings of the top 10 shareholders | ||||||||
| Name of shareholder | Nature of shareholder | Number of shares held | Percentage (%) | Number of shares held with selling restrictions | Pledge, mark or lock-up | |||
| Share status | Number | |||||||
| Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源投资有限公司) | Domestic non-state-owned legal person | 895,653,653 | 46.83 | 0 | Pledge | 75,679,725 | ||
| Hong Kong Securities Clearing Company Limited | Unknown | 94,148,526 | 4.92 | 0 | Unknown | |||
| Might Seasons Limited | Foreign legal person | 35,929,699 | 1.88 | 0 | Unknown | |||
| Perseverance Asset Management L.L.P–Gaoyi Xiaofeng No. 2 Zhixin Fund | Unknown | 16,561,348 | 0.87 | 0 | Unknown | |||
| China Foreign Economy and Trade Trust Co., Ltd.–Foreign Trust–Gaoyi Xiaofeng Hongyuan Collection Fund Trust Plan | Unknown | 16,177,148 | 0.85 | 0 | Unknown | |||
| Huaxia Life Insurance Co., Ltd. - Own fund | Unknown | 12,729,218 | 0.67 | 0 | Unknown | |||
| Abu Dhabi Investment Authority | Unknown | 10,232,971 | 0.54 | 0 | Unknown | |||
| Bank of Shanghai Co., Ltd.－Yinhua CSI Innovative Drug Industry Trading Open-end Index Securities Investment Fund | Unknown | 9,656,996 | 0.50 | 0 | Unknown | |||
| Agricultural Bank of China Limited -CSI 500 Exchange Traded Index Securities Investment Fund | Unknown | 8,405,974 | 0.44 | 0 | Unknown | |||
| CPIC Fund -China Pacific Life Insurance Co., Ltd. -with-profit insurance-CPIC Fund China Pacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan | Unknown | 7,558,834 | 0.40 | 0 | Unknown | |||
| Shareholdings of the top 10 shareholders without selling restrictions | ||||||||
| Name of shareholder | Number of tradable shares held without selling restrictions | Class and number of shares | ||||||
| Class of shares | Number | |||||||
| Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源投资有限公司) | 895,653,653 | Ordinary shares denominated in Renminbi | 895,653,653 | |||||
| Hong Kong Securities Clearing Company Limited | 94,148,526 | Ordinary shares denominated in Renminbi | 94,148,526 | |||||
| Might Seasons Limited | 35,929,699 | Ordinary shares denominated in Renminbi | 35,929,699 | |||||
| Perseverance Asset Management L.L.P–Gaoyi Xiaofeng No. 2 Zhixin Fund | 16,561,348 | Ordinary shares denominated in Renminbi | 16,561,348 | |||||
| China Foreign Economy and Trade Trust Co., Ltd.–Foreign Trust–Gaoyi Xiaofeng Hongyuan Collection Fund Trust Plan | 16,177,148 | Ordinary shares denominated in Renminbi | 16,177,148 | |||||
| Huaxia Life Insurance Co., Ltd. - Own fund | 12,729,218 | Ordinary shares denominated in Renminbi | 12,729,218 | |||||
| Abu Dhabi Investment Authority | 10,232,971 | Ordinary shares denominated in Renminbi | 10,232,971 | |||||
| Bank of Shanghai Co., Ltd.－Yinhua CSI Innovative Drug Industry Trading Open-end Index Securities Investment Fund | 9,656,996 | Ordinary shares denominated in Renminbi | 9,656,996 | |||||
| Agricultural Bank of China Limited -CSI 500 Exchange Traded Index Securities Investment Fund | 8,405,974 | Ordinary shares denominated in Renminbi | 8,405,974 | |||||
| CPIC Fund -China Pacific Life Insurance Co., Ltd. -with-profit insurance-CPIC Fund China Pacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan | 7,558,834 | Ordinary shares denominated in Renminbi | 7,558,834 | |||||
| Description of connection or acting-in-concert relationship of the above shareholders | There was no connection or acting-in-concert relationship between Shenzhen Baiyeyuan Investment Co., Ltd., a controlling shareholder of the Company, and other shareholders; whether there is connection or acting-in-concert relationship among other shareholders is unknown. |
| Description of the participation of the top 10 shareholders and the top 10 shareholders without selling restrictions in margin financing and securities lending and refinancing business (if any) | N/A |
| Description of the special repurchase account among the top 10 shareholders | As of the end of the Reporting Period, the special repurchase account of the Company (Special securities repurchase account of Joincare Pharmaceutical Group Industry Co., Ltd.) owned 46,513,711 shares in total, accounting for 2.43%. |
III. OTHER REMINDERSOther important information regarding the Company’s operations during the Reporting Period to whichinvestors should be reminded to pay attention.
□Applicable √N/A
IV. QUARTERLY FINANCIAL STATEMENTS(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
Consolidated Balance Sheet
30 September 2023Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | 30 September 2023 | 31 December 2022 |
| Current assets: | ||
| Cash and bank balances | 14,411,629,365.32 | 14,808,488,110.96 |
| Financial assets held for trading | 73,193,659.40 | 109,015,664.98 |
| Notes receivable | 2,081,418,640.69 | 1,959,985,016.85 |
| Accounts receivable | 2,939,748,117.45 | 3,103,758,850.15 |
| Receivables financing | ||
| Prepayments | 421,312,293.00 | 364,265,142.57 |
| Other receivables | 64,768,235.54 | 52,535,740.14 |
| Including: Interests receivable | ||
| Dividends receivable | ||
| Inventories | 2,717,381,235.93 | 2,561,869,999.57 |
| Contract assets | ||
| Assets held-for-sale | ||
| Non-current assets due within one year | 362,830,383.78 | 54,048,611.11 |
| Other current assets | 166,958,865.87 | 163,539,900.32 |
| Total current assets | 23,239,240,796.98 | 23,177,507,036.65 |
| Non-current assets: | ||
| Debt investment | ||
| Other debt investment | ||
| Long-term receivables | ||
| Long-term equity investment | 1,446,149,124.12 | 1,419,882,594.59 |
| Other equity instrument investments | 1,141,445,217.03 | 1,193,958,879.05 |
| Other non-current financial assets | ||
| Investment properties | 6,191,475.43 | 6,191,475.43 |
| Fixed assets | 5,683,766,148.57 | 5,265,200,110.91 |
| Construction in progress | 562,135,145.68 | 811,300,068.96 |
| Productive biological assets | ||
| Oil and gas assets | ||
| Right-of-use assets | 35,342,825.78 | 41,843,133.97 |
| Intangible assets | 701,729,275.21 | 802,115,125.75 |
| Development expenditures | 424,798,732.53 | 428,284,884.17 |
| Goodwill | 636,339,503.82 | 614,468,698.73 |
| Long-term prepaid expenses | 293,226,959.06 | 277,867,716.95 |
| Deferred income tax assets | 531,621,736.93 | 533,861,743.26 |
| Other non-current assets | 1,067,682,314.95 | 1,156,772,182.99 |
| Total non-current assets | 12,530,428,459.11 | 12,551,746,614.76 |
| Total assets | 35,769,669,256.09 | 35,729,253,651.41 |
| Current liabilities: | ||
| Short-term loans | 1,776,144,861.11 | 2,126,050,615.06 |
| Financial liabilities held for trading | 10,966,528.06 | 755,634.43 |
| Notes payable | 1,530,559,158.55 | 1,635,906,989.22 |
| Accounts payable | 906,022,129.06 | 943,905,580.91 |
| Receipts in advance | ||
| Contract liabilities | 75,564,862.24 | 292,977,730.74 |
| Employee benefits payable | 499,860,346.48 | 573,010,571.46 |
| Taxes payable | 307,862,506.00 | 337,702,273.73 |
| Other payables | 3,752,472,841.38 | 3,680,334,360.88 |
| Including: Interests payable | ||
| Dividends payable | 14,641,641.87 | 12,252,074.84 |
| Liabilities held-for-sale | ||
| Non-current liabilities due within one year | 71,269,180.31 | 63,077,260.98 |
| Other current liabilities | 45,432,846.70 | 101,276,714.35 |
| Total current liabilities | 8,976,155,259.89 | 9,754,997,731.76 |
| Non-current liabilities: | ||
| Long-term loans | 3,940,728,610.19 | 3,230,844,042.88 |
| Bonds payable | ||
| Lease liabilities | 14,438,999.56 | 23,482,486.07 |
| Long-term payables | ||
| Long-term payroll payable | ||
| Estimated liabilities | ||
| Deferred income | 412,897,139.98 | 384,537,267.55 |
| Deferred income tax liabilities | 241,853,901.75 | 231,164,425.48 |
| Other non-current liabilities | 90,000,000.00 | 84,000,000.00 |
| Total non-current liabilities | 4,699,918,651.48 | 3,954,028,221.98 |
| Total liabilities | 13,676,073,911.37 | 13,709,025,953.74 |
| Owner's equity (or shareholder's equity): | ||
| Paid-in capital (or Share capital) | 1,912,448,568.00 | 1,929,189,374.00 |
| Other equity instruments | ||
| Including: Preferred shares | ||
| Perpetual debts | ||
| Capital reserve | 2,044,380,284.45 | 2,343,693,215.99 |
| Less: Treasury shares | 564,252,205.84 | 347,176,561.29 |
| Other comprehensive income | 5,710,233.93 | 4,704,473.53 |
| Special reserve | ||
| Surplus reserve | 734,905,013.97 | 734,766,581.50 |
| Undistributed profits | 9,204,746,317.01 | 8,456,643,326.82 |
| Total owner's equity (or shareholder's equity) attributable to the parent | 13,337,938,211.52 | 13,121,820,410.55 |
| Minority shareholder's equity | 8,755,657,133.20 | 8,898,407,287.12 |
| Total owner's equity (or shareholder's equity) | 22,093,595,344.72 | 22,020,227,697.67 |
| Total liabilities and owner's equity (or shareholder's equity) | 35,769,669,256.09 | 35,729,253,651.41 |
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department:
Qiu Qingfeng
Consolidated Income Statement
From January to September, 2023Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First three quarters (January to September) of 2023 | First three quarters (January to September) of 2022 |
| I. Total revenues | 12,651,257,386.44 | 13,011,966,738.16 |
| Including: Operating revenues | 12,651,257,386.44 | 13,011,966,738.16 |
| II. Total operating costs | 9,992,088,727.85 | 10,347,452,908.46 |
| Including: Operating costs | 4,836,588,741.76 | 4,590,752,440.39 |
| Tax and surcharges | 150,278,107.37 | 148,072,490.55 |
| Selling expenses | 3,428,038,993.64 | 3,893,351,191.76 |
| Administrative expenses | 680,009,158.86 | 813,143,493.11 |
| R&D expenses | 1,211,596,866.40 | 1,232,505,100.33 |
| Financial expenses | -314,423,140.18 | -330,371,807.68 |
| Including: Interest expenses | 106,424,878.84 | 95,844,022.98 |
| Interest income | 373,189,603.11 | 296,268,948.39 |
| Add: Other income | 150,725,832.49 | 142,661,731.19 |
| Investments income (“-” for loss) | 58,569,845.80 | 48,386,584.36 |
| Including: Income from investments in associates and joint ventures | 57,873,393.21 | 52,468,548.10 |
| Gains from derecognition of financial assets at amortized cost | ||
| Gains from net exposure hedges (“-” for loss) | ||
| Gains from changes in fair values (“-” for loss) | -46,003,628.22 | -86,989,533.83 |
| Credit impairment loss (“-” for loss) | -17,737,505.85 | -9,508,656.53 |
| Assets impairment loss (“-” for loss) | -108,440,945.45 | -142,159,872.24 |
| Gains from disposal of assets (“-” for loss) | -200,478.63 | 1,121,679.66 |
| III. Operating profit (“-” for loss) | 2,696,081,778.73 | 2,618,025,762.31 |
| Add: Non-operating income | 6,302,873.99 | 4,995,275.26 |
| Less: Non-operating expenses | 23,765,998.31 | 13,738,456.89 |
| IV. Total profit (“-” for loss) | 2,678,618,654.41 | 2,609,282,580.68 |
| Less: Income tax expenses | 433,823,342.57 | 408,012,299.49 |
| V. Net profit (“-” for loss) | 2,244,795,311.84 | 2,201,270,281.19 |
| (I) Classified by business continuity | ||
| 1. Net profit from continuing operation (“-” for loss) | 2,244,795,311.84 | 2,201,270,281.19 |
| 2. Net profit from discontinued operation (“-” for loss) | ||
| (II) Classified by ownership | ||
| 1.Net profit attributable to shareholders of the parent company (“-” for loss) | 1,083,649,154.75 | 1,126,561,953.23 |
| 2.Profit and loss of minority shareholders (“-” for loss) | 1,161,146,157.09 | 1,074,708,327.96 |
| VI. Other comprehensive income, net of tax | -22,658,520.87 | 80,412,282.94 |
| (I) Other comprehensive income attributable to owners of the parent, net of tax | 1,005,760.40 | 31,984,064.97 |
| 1. Other comprehensive income that cannot be reclassified into profit or loss | -31,488,647.75 | 12,029,097.03 |
| (1) Changes from remeasurement of defined benefit plans | ||
| (2) Other comprehensive income that cannot be reclassified into profit or loss under the equity method | 0.00 | 1,173,144.60 |
| (3) Changes in fair value of investments in other equity instruments | -31,488,647.75 | 10,855,952.43 |
| (4) Changes in fair value of the enterprise's own credit risks | ||
| 2. Other comprehensive income that will be reclassified into profit or loss | 32,494,408.15 | 19,954,967.94 |
| (1) Other comprehensive income that can be reclassified into profit or loss under the equity method | 164,225.81 | 0.00 |
| (2) Changes in fair value of other debt investments | ||
| (3) Amount of financial assets reclassified into other comprehensive income | ||
| (4) Provision for credit impairment of other debt investments | ||
| (5) Reserve for cash flow hedges | ||
| (6) Exchange translation differences on financial statements denominated in foreign currencies | 32,330,182.33 | 19,954,967.94 |
| (7) Others | ||
| (II) Other comprehensive income attributable to minority shareholders, net of tax | -23,664,281.27 | 48,428,217.97 |
| VII. Total comprehensive income | 2,222,136,790.97 | 2,281,682,564.13 |
| (I) Total comprehensive income attributable to owners of the parent | 1,084,654,915.15 | 1,158,546,018.20 |
| (II) Total comprehensive income attributable to minority shareholders | 1,137,481,875.82 | 1,123,136,545.93 |
| VIII. Earnings per share: | ||
| (I) Basic earnings per share (RMB/share) | 0.5682 | 0.5983 |
| (II) Diluted earnings per share (RMB/share) | 0.5663 | 0.5971 |
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department:
Qiu Qingfeng
Consolidated Cash Flow Statement
From January to September, 2023Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First three quarters (January to September) of 2023 | First three quarters (January to September) of 2022 |
| I. Cash flows from operating activities: | ||
| Cash received from sales of goods or rendering of services | 13,510,230,759.20 | 13,705,807,329.89 |
| Tax refunds received | 141,490,762.85 | 219,263,256.92 |
| Other cash received related to operating activities | 620,955,869.98 | 536,180,845.96 |
| Subtotal of cash inflow from operating activities | 14,272,677,392.03 | 14,461,251,432.77 |
| Cash paid for goods and services | 4,573,141,561.87 | 4,180,212,054.68 |
| Cash paid to and on behalf of employees | 1,764,671,591.22 | 1,797,221,409.89 |
| Payments of all types of taxes | 1,416,153,712.56 | 1,293,188,165.95 |
| Other cash paid related to operating activities | 4,058,858,781.68 | 4,581,637,269.28 |
| Subtotal of cash outflow in operating activities | 11,812,825,647.33 | 11,852,258,899.80 |
| Net cash flows from operating activities | 2,459,851,744.70 | 2,608,992,532.97 |
| II. Cash flows from investing activities: | ||
| Cash received from disposal of investments | 390,344,459.46 | 216,970,980.42 |
| Cash received from investment income | 70,124,524.03 | 121,905,782.77 |
| Net cash received from disposal of fixed assets, intangible assets and other long-term assets | 8,042,426.01 | 1,307,684.20 |
| Net cash received from disposal of subsidiaries and other business units | ||
| Other cash received related to investing activities | 297,590,000.00 | 13,356,765.87 |
| Subtotal of cash inflows from investing activities | 766,101,409.50 | 353,541,213.26 |
| Cash paid for purchase and construction of fixed assets, intangible assets and other long-term assets | 753,228,828.13 | 975,980,046.68 |
| Cash paid to acquire investments | 439,136,113.68 | 37,995,968.80 |
| Net cash paid for acquisition of subsidiaries and other business units | 22,461,951.59 | 0.00 |
| Other cash paid related to investing activities | 227,027,492.56 | 226,494,395.22 |
| Subtotal of cash outflows in investing activities | 1,441,854,385.96 | 1,240,470,410.70 |
| Net cash flows from investing activities | -675,752,976.46 | -886,929,197.44 |
| III. Cash flows from financing activities: | ||
| Cash received from capital contribution | 18,056,784.20 | 719,365,346.09 |
| Including: Cash received from investment by minority interests of subsidiaries | 6,700,000.00 | 0.00 |
| Cash received from borrowings | 3,347,170,168.70 | 5,297,022,796.00 |
| Other cash received related to financing activities | 20,000,000.00 | 303,958,487.50 |
| Subtotal of cash inflows from financing activities | 3,385,226,952.90 | 6,320,346,629.59 |
| Cash repayments of amounts borrowed | 2,592,352,425.04 | 3,504,080,892.47 |
| Cash payments for interest expenses and distribution of dividends or profits | 1,570,166,936.38 | 1,314,118,888.43 |
| Including: Dividends and profit paid to minority interests of subsidiaries | 1,120,761,303.69 | 960,193,396.67 |
| Other cash payments related to financing activities | 1,210,358,606.39 | 628,305,503.73 |
| Subtotal of cash outflows from financing activities | 5,372,877,967.81 | 5,446,505,284.63 |
| Net cash flows from financing activities | -1,987,651,014.91 | 873,841,344.96 |
| IV. Effect of exchange rate changes on cash and cash equivalents | 71,991,155.94 | 227,244,304.84 |
| V. Net increase in cash and cash equivalents | -131,561,090.73 | 2,823,148,985.32 |
| Add: Opening balance of cash and cash equivalents | 14,178,465,686.40 | 11,697,518,141.18 |
| VI. Closing balance of cash and cash equivalents | 14,046,904,595.67 | 14,520,667,126.50 |
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department:
Qiu Qingfeng
(Ⅲ) Implementation of new accounting standards or interpretations of standards, for the third time from2023 involves adjustments to the financial statements at the beginning of the year
□Applicable √N/A
Hereby the announcement is made.
Joincare Pharmaceutical Group Industry Co., Ltd.
25 October, 2023